Tyco International acquired Mallinckrodt in a stock-swap valued at ~$4.2B ($47.50/share). Mallinckrodt brought medical imaging, respiratory care, and analgesic pharmaceuticals businesses with FY1999 revenues of $2.6B. FTC settlement preserved competition in endotracheal tubes. Closed Oct 2000.
Did it work? Outcome assessment
Strategic verdict
Partially Achieved
Financial impact
Neutral
Pipeline outcome
Assets Advanced
Assessment window: 10yr post-close.
Key facts
AnnouncedJun 28, 2000
ClosedOct 17, 2000
Deal value$4.2B
Deal typeAcquisition/Merger
Therapeutic areaImaging / pain / respiratory
IndicationsImaging / pain / respiratory
Key assetsMedical imaging contrast agents, respiratory care, opioid analgesics